Core Viewpoint - The company, 加科思药业, has demonstrated strong confidence in its fundamentals and long-term growth prospects through significant share buybacks and insider purchases by its CEO and associates [1] Group 1: Stock Performance - 加科思-B (01167) shares rose over 3%, specifically by 3.28%, reaching HKD 9.45, with a trading volume of HKD 30.1853 million [1] Group 2: Insider Transactions - The company's chairman and CEO, Dr. Wang Yinxiang, along with associates, invested nearly HKD 100 million to purchase over 11.05 million shares [1] Group 3: Share Buyback Program - The previously announced HKD 100 million share buyback program has commenced, with approximately HKD 26.7 million executed so far, and it is expected to continue over the next year [1] Group 4: Business Operations and Product Pipeline - The company reported that its business operations are currently in good condition, with encouraging progress in the development of its core product pipeline, including the Pan-KRAS inhibitors [1]
加科思-B涨超3% 董事长及一致行动人斥资近1亿港元增持股份